AEterna Zentaris Inc. (AEZS)

[alexander77]

DSMB-safety/efficacy evaluation-early October

Option 1. DSMB advices to continue the trial
Option 2. DSMB advices for immediate FDA approval based on superior safety and efficacy
Option 3. DSMB advices to end the trial b/c of lack of efficacy

Price estimates:
Option 1. $.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes
1.23=consensus price target of 5 analysts

Option 2. at least $3.5/share or a market cap of 2.5 billion dollar
ZopTec will then be the only FDA approved treatment for endometrial cancer with possible 750 million dollar ANNUAL revenu in the US+Europe (Sinopharm royalties for China, Macau and Hong Kong not included)

Option 3. $.10 based on their latest cash position of $45m and Saizen+Estrogel revenues